A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes ( AWARD‐JPN )
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15644 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Tomoaki Morioka und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Blood Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly Japan.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To assess the efficacy and safety of dulaglutide 1.5 mg versus dulaglutide 0.75 mg in Japanese participants with type 2 diabetes (T2D). Materials and Methods A Phase 3, multicentre, randomized, double‐blind, parallel‐group study was conducted in Japanese participants aged ≥20 years, with T2D for ≥6 months and inadequate glycaemic control, while on a single oral antihyperglycaemic medication (NCT04809220). The primary objective was to evaluate superiority of dulaglutide 1.5 mg versus dulaglutide 0.75 mg measured by mean change in glycated haemoglobin (HbA1c) from baseline to 26 weeks. Other efficacy and safety endpoints were evaluated at 26 and 52 weeks. All statistical analyses were conducted using the intention‐to‐treat population.
Results
Overall, 591 participants were randomized to once‐weekly dulaglutide 1.5 mg or 0.75 mg. At Week 26, dulaglutide 1.5 mg was superior to dulaglutide 0.75 mg in HbA1c reduction from baseline (least squares mean [LSM] difference −0.29% [95% confidence interval {CI} −0.43, −0.14]). At Week 52, the dulaglutide 1.5‐mg arm had a significantly greater proportion of participants who achieved HbA1c
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
- Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan.
ORCID-Profile: Masakazu Takeuchi
Förderung
- Eli Lilly Japan
Zitieren
APA
Morioka, T., Takeuchi, M., Ozeki, A., & Emoto, M. (2024). A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes ( AWARD‐JPN ). Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15644
Vancouver
Morioka T, Takeuchi M, Ozeki A, Emoto M. A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes ( AWARD‐JPN ). Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15644
BibTeX
@article{Morioka2024,
author = {Morioka, Tomoaki and Takeuchi, Masakazu and Ozeki, Akichika and Emoto, Masanori},
title = {A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes ( AWARD‐JPN )},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15644}
}
EUVIMED